NCT04939051 2026-03-18
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06732388 2026-03-18
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02521285 2025-10-23
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03223662 2018-10-30
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00004236 2014-06-24
Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005876 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00077545 2013-10-08
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098527 2013-07-02
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006245 2013-06-24
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00032123 2013-06-24
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045526 2013-06-04
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00061958 2013-01-23
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003326 2008-07-24
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown